Most pages about a supplement are written about the studies where it worked. This one is about a study where it did not, and that is the reason it is worth reading.
In 2013 a group published a prospective, randomized, double-blind, placebo-controlled trial of hydrogen-rich water in patients with interstitial cystitis, also called painful bladder syndrome[1]. The authors’ own stated conclusion is that the results do not support the use of hydrogen-rich water for this condition. That conclusion has stood unchallenged for over a decade.
Why this trial is unusually well designed
Interstitial cystitis is a chronic bladder pain condition with fluctuating symptoms and no reliable objective marker. Conditions shaped like that are exactly where weak study designs produce false positives, because symptoms that come and go will often be improving anyway at the moment someone starts a new treatment.
This trial anticipated most of that. It was double-blind, so neither participants nor assessors knew who got what. It was placebo-controlled with a placebo water, so the act of drinking extra fluid on a schedule was matched. It enrolled only patients whose symptoms had been stable for at least twelve weeks after bladder hydrodistension, which filters out people who are still in the middle of recovering from a procedure. And it required a minimum symptom burden at entry: an Interstitial Cystitis Symptom Index score of at least seven and a bladder pain score of at least four[1].
Participants were randomized in a two-to-one ratio to hydrogen-rich water or placebo water for eight weeks. Thirty people were enrolled, twenty-nine women and one man, with a mean age of sixty-four years plus or minus 14.8. Two women withdrew[1].
Outcomes were measured with the Interstitial Cystitis Symptom Index, the Interstitial Cystitis Problem Index, the Parsons Pelvic Pain and Urgency and Frequency scale, a visual analogue scale for bladder pain, and a standard three-day voiding diary[1]. That is a thorough panel rather than a single convenient endpoint.
What it found
Bladder pain scores fell significantly in both groups. But the effect of hydrogen-rich water on symptoms was not significantly different from placebo[1].
Those two sentences are the whole result, and the order matters. People got better. The hydrogen did not explain why.
The authors’ conclusion is unambiguous: the results of the study do not support the use of supplementation with hydrogen-rich water for treating patients with interstitial cystitis or painful bladder syndrome[1].
The eleven percent, and why it does not rescue the result
There is one finding that gets quoted out of context. The abstract notes that hydrogen-rich water was extremely effective in improving the bladder pain score in eleven percent of the patients[1].
It is tempting to read that as “it works for some people”. Here is why that reading does not survive contact with the design.
First, the trial does not report that the placebo arm had zero strong responders. It reports the responder figure for the hydrogen arm. Without the matching placebo figure, an eleven percent response rate is not evidence of anything, because placebo arms in this field routinely produce strong responders too.
Second, and more fundamentally, in a fluctuating pain condition some people will improve markedly during any eight-week window regardless of treatment. Picking out the people who improved most, after the fact, and attributing their improvement to the treatment is the oldest error in clinical research. It is precisely what a control group exists to prevent, and this trial had one.
Third, eleven percent of roughly twenty-eight completing participants is about three people. Three people improving markedly is not a subgroup. It is a handful.
The placebo response is the real story
Pain fell significantly in both arms. That is not a failure of the trial, it is a genuine and well-documented phenomenon in this exact clinical area.
Placebo and nocebo effects have been demonstrated repeatedly across functional urology, including in overactive bladder, urinary incontinence, lower urinary tract symptoms and interstitial cystitis and painful bladder syndrome specifically[2]. The effect is partly driven by the positive expectations of the person receiving treatment, and it is large enough that understanding it is treated as part of clinical practice rather than as a statistical nuisance[2].
This is why an uncontrolled study of hydrogen water in interstitial cystitis would almost certainly have reported a success. Give thirty people with fluctuating bladder pain a new treatment, a schedule to follow and eight weeks of attention, measure them before and after, and the numbers will improve. The only way to find out whether the substance did anything is to run the arm that this trial ran.
What this does and does not tell you about hydrogen generally
It tells you about hydrogen-rich water, taken orally, for eight weeks, in interstitial cystitis, in a group of mostly older women with established stable disease. It does not tell you that molecular hydrogen does nothing in general, and it should not be stretched that way.
The underlying mechanism claim, that hydrogen selectively reduces hydroxyl radical while sparing useful signalling radicals[3], is not refuted by a negative trial in one condition. Plenty of compounds with real biological activity fail in specific diseases, because a mechanism being real is not the same as it being decisive for a given problem.
What the trial does establish is that for this condition, in a properly controlled design, the substance did not beat water.
Why a negative result is worth publishing and worth reading
Negative trials are underrepresented in supplement coverage for an obvious reason: nobody sells anything with them. That skews the impression a reader forms from browsing, because the positive studies are the ones that get written about.
For anyone with interstitial cystitis, this result is directly useful. It means that if you are considering hydrogen water for bladder pain, the single best piece of evidence available tested it against placebo and found no advantage. That saves money and, more importantly, saves time that could go toward treatments with better support.
It also gives you a reference point for evaluating claims. If you encounter marketing that mentions hydrogen water for bladder pain, this is the trial to ask about.
The bottom line
A prospective, randomized, double-blind, placebo-controlled trial randomized thirty patients with interstitial cystitis or painful bladder syndrome in a two-to-one ratio to hydrogen-rich water or placebo water for eight weeks. Bladder pain improved significantly in both groups, and hydrogen-rich water was not significantly better than placebo. The authors concluded that the results do not support its use[1].
An eleven percent strong-responder rate in the treatment arm is not a counterargument, because no matching placebo responder rate is reported and the numbers involved are tiny.
The improvement seen in both arms is a textbook illustration of the placebo response that is well documented throughout functional urology[2], and it is the reason this trial needed a control group to be worth anything at all.
For a broader look at where the evidence is stronger and weaker across conditions, see our overview of what the critical reviews of molecular hydrogen say.
References
- Effect of supplementation with hydrogen-rich water in patients with interstitial cystitis/painful bladder syndrome. Urology, 2013
- The placebo and nocebo effects in functional urology. Nature Reviews Urology, 2022
- Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nature Medicine, 2007
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
